Exhibit 99.1
 
Press Release
 
Regeneron Reports Fourth Quarter and Full Year 2014 Financial and Operating Results
Fourth quarter 2014 EYLEA® (aflibercept) Injection global net sales increased 39% to $815 million (consisting of $518 million in the U.S. and $297 million in rest of world(1) ) versus fourth quarter 2013
Full year 2014 EYLEA global net sales increased 48% to $2.78 billion (consisting of $1.74 billion in the U.S. and $1.04 billion in rest of world(1) ) versus full year 2013
Fourth quarter 2014 non-GAAP net income(2) increased 27% to $328 million, or $2.79 per diluted share. Full year 2014 non-GAAP net income(2) increased 26% to $1.17 billion, or $10.00 per diluted share.
Tarrytown, New York (February 10, 2015)
-- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2014 and provided an update on development programs.
Financial Highlights
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
($ in millions, except per share data)
 
Three Months Ended
December 31,
 
Year Ended
December 31,
 
 
2014
 
2013
 
% Change
 
2014
 
2013
 
% Change
EYLEA U.S. net product sales
 
$
518

 
$
402

 
29
%
 
$
1,736

 
$
1,409

 
23
%
Total revenues
 
$
802

 
$
610

 
31
%
 
$
2,820

 
$
2,105

 
34
%
Non-GAAP net income
 
$
328

 
$
259

 
27
%
 
$
1,175

 
$
935

 
26
%
Non-GAAP net income per share - diluted
 
$
2.79

 
$
2.24

 
25
%
 
$
10.00

 
$
8.17

 
22
%
GAAP net income
 
$
110

 
$
97

 
13
%
 
$
348

 
$
424

 
(18
%)
GAAP net income per share - diluted
 
$
0.96

 
$
0.86

 
12
%
 
$
3.07

 
$
3.81

 
(19
%)
 
 
 
 
 
 
 
 
 
 
 
 
 

"In 2015, Regeneron continues on our mission to evolve into a company with multiple, commercially-important therapies for patients," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. "We look forward to another strong year of EYLEA growth, driven by expanded use in diabetic macular edema, as well as the potential regulatory approval and U.S. launch of PRALUENT for hypercholesterolemia. Regeneron also continues to advance our innovative mid-to-late stage pipeline of antibodies for people with serious diseases including rheumatoid arthritis, atopic dermatitis, asthma, chronic pain, and a life-threatening infection."

1

The following information was filed by Regeneron Pharmaceuticals Inc (REGN) on Tuesday, February 10, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Regeneron Pharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Regeneron Pharmaceuticals Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account